Sustained delivery fluocinolone acetonide vitreous implants: Long-term benefit in patients with chronic diabetic macular edema

Ophthalmology

Volumn 121, Issue 10, 2014, Pages 1892-1903.e3

  Cunha Vaz, José ^a   Ashton, Paul ^b   Iezzi, Raymond ^c   Campochiaro, P A ^m   Dugel, Pravin U ^e   Holz, Frank G ^f   Weber, Michel ^g   Danis, Ronald P ^h   Kuppermann, Baruch D ⁱ   Bailey, Clare ^j   Billman, Kathleen ^k   Kapik, Barry ^k   Kane, Frances ^l   Green, Ken ^k   Brown, D M ^m   Pearson, A ^m  

^a ASSOCIATION FOR INNOVATION AND BIOMEDICAL RESEARCH ON LIGHT AND IMAGE AIBILI   (Portugal)

^b pSiMedica Ltd   (United Kingdom)

^c MAYO CLINIC   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e RETINAL CONSULTANTS OF ARIZONA   (United States)

^f UNIVERSITY OF BONN   (Germany)

^g HÔTEL DIEU   (France)

^h UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j BRISTOL EYE HOSPITAL   (United Kingdom)

^k Alimera Sciences Limited   (United States)

^l Apropos Pharmaceutical Consulting LLC   (United States)

^m NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

FLUOCINOLONE ACETONIDE; INSULIN; ORAL ANTIDIABETIC AGENT; TRIAMCINOLONE ACETONIDE; ANTIINFLAMMATORY AGENT;

ADULT; ARTICLE; CATARACT; CENTRAL RETINAL THICKNESS; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INSULIN TREATMENT; INTRAOCULAR HYPERTENSION; INTRAVITREAL IMPLANT; LONG TERM CARE; LOW LEVEL LASER THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPTICAL COHERENCE TOMOGRAPHY DEVICE; PARALLEL DESIGN; RANDOMIZED CONTROLLED TRIAL; RETINA FOVEA; RETREATMENT; RISK BENEFIT ANALYSIS; SUSTAINED DRUG RELEASE; VISION; VISUAL ACUITY; AGED; CHRONIC DISEASE; CONTROLLED CLINICAL TRIAL; DELAYED RELEASE FORMULATION; DIABETIC RETINOPATHY; DRUG IMPLANT; MIDDLE AGED; RETINA MACULA EDEMA; VITREOUS BODY;

AGED; ANTI-INFLAMMATORY AGENTS; CHRONIC DISEASE; DELAYED-ACTION PREPARATIONS; DIABETIC RETINOPATHY; DOUBLE-BLIND METHOD; DRUG IMPLANTS; FEMALE; FLUOCINOLONE ACETONIDE; HUMANS; MACULAR EDEMA; MALE; MIDDLE AGED; VISUAL ACUITY; VITREOUS BODY;

EID: 84908121230     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2014.04.019     Document Type: Article

References (27)

1. R. Klein, B.E. Klein, and S.E. Moss The Wisconsin Epidemiologic Study of Diabetic Retinopathy. IV. Diabetic macular edema Ophthalmology 91 1984 1464 1474
2. F. Ko, S. Vitale, and C.F. Chou Prevalence of nonrefractive visual impairment in US adults and associated risk factors, 1999-2002 and 2005-2008 JAMA 308 2012 2361 2368
3. J. Ding, and T.Y. Wong Current epidemiology of diabetic retinopathy and diabetic macular edema Curr Diab Rep 12 2012 346 354
4. Early Treatment Diabetic Retinopathy Study Research Group Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1 Arch Ophthalmol 103 1985 1796 1806
5. A. Yanyali, F. Horozoglu, E. Celik, and A.F. Nohutcu Long-term outcomes of pars plana vitrectomy with internal limiting membrane removal in diabetic macular edema Retina 27 2007 557 566
6. A. Yanyali, A.F. Nohutcu, F. Horozoglu, and E. Celik Modified grid laser photocoagulation versus pars plana vitrectomy with internal limiting membrane removal in diabetic macular edema Am J Ophthalmol 139 2005 795 801
7. H. Funatsu, H. Yamashita, and H. Noma Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema Am J Ophthalmol 133 2002 70 77
8. Lucentis (ranibizumab injection) [package insert] 2014 Genentech, Inc South San Francisco, CA Available at: http://www.gene.com/download/pdf/lucentis-prescribing.pdf Accessed April 17, 2014
9. Q.D. Nguyen, D.M. Brown, D.M. Marcus RISE and RIDE Research Group Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE Ophthalmology 119 2012 789 801
10. Diabetic Retinopathy Clinical Research Network M.J. Elman, L.P. Aiello, and R.W. Beck Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema Ophthalmology 117 2010 1064 1077
11. D.M. Brown, Q.D. Nguyen, D.M. Marcus RIDE and RISE Research Group Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE Ophthalmology 120 2013 2013 2022
12. Diabetic Retinopathy Clinical Research Network M.J. Elman, N.M. Bressler, and H. Qin Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema Ophthalmology 118 2011 609 614
13. ClinicalTrials.gov. Diabetic Retinopathy Clinical Research Network. Phase II combination steroid and anti-VEGF for persistent DME. ClinicalTrials.gov identifier NCT01945866. Available at: http://clinicaltrials.gov/ct2/show/NCT01945866. Accessed March 24, 2014.
14. P.A. Campochiaro, D.M. Brown, A. Pearson FAME Study Group Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema Ophthalmology 118 2011 626 635
15. P.A. Campochiaro, D.M. Brown, A. Pearson FAME Study Group Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema Ophthalmology 119 2012 2125 2132
16. J. Cohen A coefficient of agreement for nominal scales Educ Psychol Meas 20 1960 37 46
17. P.A. Campochiaro, Q.D. Nguyen, G. Hafiz FAMOUS Study Group Aqueous levels of fluocinolone acetonide after administration of fluocinolone acetonide inserts or fluocinolone acetonide implants Ophthalmology 120 2013 583 587
18. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema Ophthalmology 115 2008 1447 1459
19. T.S. Kern Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy Exp Diabetes Res [serial online] 2007 2007 95103 Available at: http://www.hindawi.com/journals/jdr/2007/095103/abs/ Accessed April 17, 2014
20. H.Y. Zeng, W.R. Green, and M.O. Tso Microglial activation in human diabetic retinopathy Arch Ophthalmol 126 2008 227 232
21. M. Nauck, G. Karakiulakis, and A.P. Perruchoud Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells Eur J Pharmacol 341 1998 309 315
22. D.A. Antonetti, E.B. Wolpert, and L. DeMaio Hydrocortisone decreases retinal endothelial cell water and solute flux coincident with increased content and decreased phosphorylation of occludin J Neurochem 80 2002 667 677
23. H.L. Brooks Jr., S. Caballero Jr., and C.K. Newell Vitreous levels of vascular endothelial growth factor and stromal-derived factor 1 in patients with diabetic retinopathy and cystoid macular edema before and after intraocular injection of triamcinolone Arch Ophthalmol 122 2004 1801 1807
24. U.B. Kompella, N. Bandi, and S.P. Ayalasomayajula Subconjunctival nano- and microparticles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression Invest Ophthalmol Vis Sci 44 2003 1192 1201
25. I.V. Glybina, A. Kennedy, and P. Ashton Intravitreous delivery of the corticosteroid fluocinolone acetonide attenuates retinal degeneration in S334ter-4 rats Invest Ophthalmol Vis Sci 51 2010 4243 4252
26. I.V. Glybina, A. Kennedy, and P. Ashton Photoreceptor neuroprotection in RCS rats via low-dose intravitreal sustained-delivery of fluocinolone acetonide Invest Ophthalmol Vis Sci 50 2009 4847 4857
27. R.B. Bhisitkul, B.J. Winn, and O.T. Lee Neuroprotective effect of intravitreal triamcinolone acetonide against photoreceptor apoptosis in a rabbit model of subretinal hemorrhage Invest Ophthalmol Vis Sci 49 2008 4071 4077